2nd Quarter - Report

ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$430,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 19, 2010 $430,000 Replaced
2nd Quarter - Amendment Oct 19, 2010 $310,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues pertaining to antimicrobial resistance (the Strategies to Address Antimicrobial Resistance Act (HR 2400)). Issues pertaining to community and healthcare associated infections. Issues pertaining to medical isotopes (the American Medical Isotopes Production Act of 2009 (HR 3276)). Issues related to 340B program, follow on biologics, hospital readmissions/bundling and home infusion therapy coverage (the Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565), the Patient Protection and Affordable Care Act (HR 3590), Affordable Health Care for America Act (HR 3962), and the Health Care and Education Reconciliation Act of 2010 (HR 4872)). Issues related to oncology coverage (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)). Issues related to 340B (the American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MICHAEL RUGGIERO —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1844 (111th), H.R. 4213 (111th), H.R. 2400 (111th), H.R. 4872 (111th), H.R. 3590 (111th), H.R. 3962 (111th), H.R. 1458 (111th), H.R. 3276 (111th)

Medicare/Medicaid MMM

Issues related to hospital readmissions/bundling and home infusion therapy coverage, (the Medicare Home Infusion Therapy Coverage Act of 2009 (HR 574/S 254)) The Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act (HR 1458/S 565) Issues related to Medicare physician payment system (to amend title XVIII of the Social Security Act to continue using 2009 Medicare practice expense relative value units for certain cardiology services, (HR 4371)), and CPT codes for myocardial perfusion imaging. The Health Care and Education Reconciliation Act of 2010 (HR 4872), the Patient Protection and Affordable Care (HR 3590), and the Affordable Health Care for America Act (HR 3962). Issues related to oncology coverage and medicare clinical trials (the Comprehensive Cancer Care Improvement Act of 2009 (HR 1844)).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MICHAEL RUGGIERO —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3962 (111th), H.R. 1458 (111th), H.R. 1844 (111th), H.R. 4371 (111th), H.R. 3590 (111th), H.R. 4872 (111th), H.R. 574 (111th)

Government Issues GOV

Issues pertaining to campaign activities of certain domestic corporations (the DISCLOSE Act (HR 5175/S3295)).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MICHAEL RUGGIERO —
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5175 (111th)

Tariff (miscellaneous tariff bills) TAR

Tariff duty suspension for RSD 1235 (a bill to extend temporarily the suspension of duty on RSD 1235 (S 2753)).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MICHAEL RUGGIERO —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.